Seeking Alpha

Arrowhead Research up 16% in early trading

  • Investors like the news that Arrowhead Research (ARWR +19.8%) has received regulatory approval from the Hong Kong Department of Health to begin a phase 2a clinical trial for ARC-520, its RNAi-based drug for the treatment of chronic hepatitis B (HBV) infection.
  • The phase 2 trial will be conducted at two local hospitals involving two cohorts at two dose levels.
  • The purpose of the study is to determine the depth and duration of hepatitis B surface antigen ((HBsAg)) reduction after a single IV dose of ARC-520 in combination with entecavir in patients with chronic HBV infection.
  • Secondary measures are safety, tolerability and pharmacokinetic measures.
  • All four analysts covering the stock rate it as BUY.
  • Mutual fund ownership has increased from 11 to 45 over the past 4 quarters.
Comments (1)
  • GrowthGeek
    , contributor
    Comments (898) | Send Message
     
    Good news for $ARWR and for $BNIKF which is in the ddRNAi sector of biotech.
    5 Mar, 11:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|